Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Armata Pharmaceuticals, Inc. (ARMP)

Armata Receives $3.7 Million Additional DoW Funding for AP-SA02 Phase 3 Program

Positive Impact 3 of 5 financing Written later

Armata Pharmaceuticals said it received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support the Phase 3 program for AP-SA02, its lead clinical candidate. The company said this is the first DoW funding specifically for Phase 3 execution, and it lifts cumulative non-dilutive DoW support for the program to approximately $32.4 million, which may reduce the need to raise capital through share sales.

Key points

  • Armata received $3.7 million in additional non-dilutive funds from the U.S. Department of War, announced September 23, 2026.
  • The award is administered through the Medical Technology Enterprise Consortium and funded by the Defense Health Agency and Joint Warfighter Medical Research Program.
  • Cumulative non-dilutive DoW funding under the award is approximately $32.4 million, following $28.7 million previously provided.
  • The company plans to start a Phase 3 superiority study of AP-SA02 in complicated S. aureus bacteremia in the second half of 2026.

The filing

CompanyArmata Pharmaceuticals, Inc. (ARMP)
Form8-K, current report
Filed with the SECSep 23, 2026, 7:10 AM ET
Accession number0001104659-26-109809

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.